Dr. Ely L. Manstein

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy. Dr. Campochiaro is board certified in American Board Of Ophthalmology. Dr. Campochiaro is currently accepting new patients.

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Bressler is board certified in American Board Of Ophthalmology. Dr. Bressler is currently accepting new patients.

Dr. Susan Bressler is the Julia G. Levy, Ph.D. Professor of Ophthalmology at the Wilmer Eye Institute. She is an ophthalmologist and has subspecialty training in medical retinal disorders, vitreoretinal disease, and retinal surgery. Her main research interest has been collaborative efforts in clinical trials - serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. Dr. Bressler has a large national and international referral practice. In addition, she has published 223 peer reviewed articles and 55 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, Health After 50: The Johns Hopkins Medical Letter and the Wilmer Retina Update. Dr. Bressler is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy. Dr. Bressler is board certified in American Board Of Ophthalmology. Dr. Bressler is currently accepting new patients.

Douglas A. Jabs, M.D., M.B.A. is an internationally-recognized expert in the evaluation and management of patients with uveitis and related immune-mediated ocular disorders, particularly on the use of immunosuppression to treat severe ocular inflammatory diseases. Founder of the Division of Ocular Immunology and Uveitis at Wilmer, he now is the Director of the Center for Clinical Trials and Evidence Synthesis at the Johns Hopkins University Bloomberg School of Public Health. Dr. Jabs is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Uveitis, CMV Retinitis, Scleritis, Cataract Removal, and Trabeculectomy. Dr. Jabs is board certified in American Board Of Internal Medicine and American Board Of Ophthalmology. Dr. Jabs is currently accepting new patients.

James T. Handa, M.D., is Chief of the Retina Division and the Robert Bond Welch, M.D., Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. He has been funded by the National Eye Institute for the last 19 years, and he currently holds two R01 awards for his work in AMD. He has also been funded by the Thome Foundation, Research to Prevent Blindness, Fight for Sight and the American Health Assistance Foundation. His other research focuses on surgical innovation using an integrated robotic surgical system. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval. Dr. Handa is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Melanoma of the Eye, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Metastatic Uveal Melanoma, and Vitrectomy. Dr. Handa is board certified in American Board Of Ophthalmology. Dr. Handa is currently accepting new patients.

Dr. Harry A. Quigley is the A. Edward Maumenee Professor of Ophthalmology and developed the Glaucoma Division at the Johns Hopkins Wilmer Eye Institute. He was a founding member of the American Glaucoma Society, serving for 8 years as its Secretary and was elected to 5 year terms as chief executive officer of the Association for Research in Vision and Ophthalmology (ARVO) and editor-in-chief of Investigative Ophthalmology and Visual Science. He has published over 350 peer-reviewed articles, and his reports are the most cited in the ophthalmic literature over the last 30 years (Archives of Ophthalmology, 2007). His research has improved the early diagnosis of glaucoma and has developed instruments and techniques to identify glaucoma damage better. He has participated in pioneering studies of the epidemiology, morbidity and progression rate of glaucoma and other eye disease in American, African, Asian and Hispanic populations, serving as a consultant to the World Health Organization. In the laboratory, he has demonstrated successful gene therapy to protect retinal ganglion cells from experimental glaucoma and developed glaucoma models in monkeys, rats and mice. Dr. Quigley is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Trabeculectomy, and Iridectomy. Dr. Quigley is board certified in American Board Of Ophthalmology. Dr. Quigley is currently accepting new patients.